Spinal muscular atrophy care in the COVID-19 pandemic era

Aravindhan Veerapandiyan, Anne M. Connolly, Richard S. Finkel, Kapil Arya, Katherine D. Mathews, Edward C. Smith, Diana Castro, Russell J. Butterfield, Julie A. Parsons, Laurent Servais, Nancy Kuntz, Vamshi K. Rao, John F. Brandsema, Eugenio Mercuri, Emma Ciafaloni

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.

Original languageEnglish (US)
Pages (from-to)46-49
Number of pages4
JournalMuscle and Nerve
Issue number1
StatePublished - Jul 1 2020


  • SMA
  • corona
  • epidemic
  • guidelines
  • pandemic
  • treatment

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)


Dive into the research topics of 'Spinal muscular atrophy care in the COVID-19 pandemic era'. Together they form a unique fingerprint.

Cite this